These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38102573)

  • 41. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints.
    Jeong IH; Park B; Kim SH; Hyun JW; Joo J; Kim HJ
    Mult Scler; 2016 Mar; 22(3):329-39. PubMed ID: 26041804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder.
    Lin J; Xue B; Li J; Zhu R; Pan J; Chen Z; Zhang X; Li X; Xia J
    Front Neurol; 2022; 13():891064. PubMed ID: 35599732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: A modeling analysis of literature aggregate data.
    Luo J; Yu J; Sui Z; Zhong Y; Zheng Q; Li L
    Int Immunopharmacol; 2022 Sep; 110():109004. PubMed ID: 35785726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of the efficacy of tocilizumab versus azathioprine for neuromyelitis optica spectrum disorder: A study protocol for systematic review and meta-analysis.
    Tang Q; Yao M; Huang Y; Bian J; Wang Y; Ji W
    Medicine (Baltimore); 2023 Jan; 102(4):e32748. PubMed ID: 36705346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report.
    Li X; Wu W; Zeng Y; Wu W; Hou C; Zhu H; Liao Y; Tian Y; Chen Z; Peng B; Chen WX
    Front Immunol; 2023; 14():1257955. PubMed ID: 37915570
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort.
    Rajput HM; Hassan M; Badshah M
    Mult Scler Relat Disord; 2023 Jun; 74():104656. PubMed ID: 37068371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate.
    Yang Y; Chen L; Wu L; Yao J; Wang N; Su X; Li D; Han L; Wu W; Huang D; Jiang T; Wang Z
    Neurol Ther; 2022 Mar; 11(1):137-149. PubMed ID: 34797551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intestinal Barrier Breakdown and Mucosal Microbiota Disturbance in Neuromyelitis Optical Spectrum Disorders.
    Cui C; Tan S; Tao L; Gong J; Chang Y; Wang Y; Fan P; He D; Ruan Y; Qiu W
    Front Immunol; 2020; 11():2101. PubMed ID: 32983166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica.
    Qiu W; Kermode AG; Li R; Dai Y; Wang Y; Wang J; Zhong X; Li C; Lu Z; Hu X
    J Clin Neurosci; 2015 Jul; 22(7):1178-82. PubMed ID: 26006157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gut Microbiome and Bile Acid Metabolism Induced the Activation of CXCR5+ CD4+ T Follicular Helper Cells to Participate in Neuromyelitis Optica Spectrum Disorder Recurrence.
    Cheng X; Zhou L; Li Z; Shen S; Zhao Y; Liu C; Zhong X; Chang Y; Kermode AG; Qiu W
    Front Immunol; 2022; 13():827865. PubMed ID: 35126400
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adverse Events in NMOSD Therapy.
    Giglhuber K; Berthele A
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China.
    Huang W; Tan H; Xia J; Li W; Li X; ZhangBao J; Chang X; Wang L; Wang M; Zhao C; Lu J; Lu C; Dong Q; Zhou L; Quan C;
    Mult Scler Relat Disord; 2022 Oct; 66():104023. PubMed ID: 35843144
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies.
    Luo D; Wei R; Tian X; Chen C; Ma L; Li M; Dong X; Zhang E; Zhou Y; Cui Y
    Mult Scler Relat Disord; 2020 Nov; 46():102484. PubMed ID: 32932167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of short-chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: A Chinese pilot study.
    Gong J; Qiu W; Zeng Q; Liu X; Sun X; Li H; Yang Y; Wu A; Bao J; Wang Y; Shu Y; Hu X; Bellanti JA; Zheng SG; Lu Y; Lu Z
    Mult Scler; 2019 Aug; 25(9):1316-1325. PubMed ID: 30113252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Analysis of Treatment Outcomes in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab, Azathioprine, and Mycophenolate Mofetil: A Systematic Review and Meta-analysis.
    Magdalena C; Clarissa A; Sutandi N
    Innov Clin Neurosci; 2022; 19(4-6):51-64. PubMed ID: 35958974
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder.
    Wang L; Tan H; Huang W; ZhangBao J; Chang X; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Mult Scler Relat Disord; 2021 Feb; 48():102707. PubMed ID: 33383362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil.
    Flannigan KL; Taylor MR; Pereira SK; Rodriguez-Arguello J; Moffat AW; Alston L; Wang X; Poon KK; Beck PL; Rioux KP; Jonnalagadda M; Chelikani PK; Galipeau HJ; Lewis IA; Workentine ML; Greenway SC; Hirota SA
    J Heart Lung Transplant; 2018 Sep; 37(9):1047-1059. PubMed ID: 30173823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.